Department of Pathology and Laboratory Medicine, Clinical Genomics, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Department of Pathology, Clinical Genomics, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Biopreserv Biobank. 2021 Apr;19(2):136-142. doi: 10.1089/bio.2020.0131. Epub 2021 Feb 9.
Dry blood spots (DBS) offer many advantages over other blood banking protocols due to the reduction of time and equipment needed for collection and the ease of processing, storage, and shipment. In addition, the sample size makes it a very attractive method when considering the banking of small pediatric samples. On that note, the Centers for Disease Control and Prevention (CDC) preanalytical standards for DBS are commonly used in the worldwide mass spectrometry-based inborn errors of metabolism screening programs. However, these guidelines may not apply for analytes and protocols not included in these programs. In fact, the availability of leftover samples and the ongoing interest in protocols outside this scenario are providing us with new DBS biobanking insights. Herein, we review the literature for indicators that should be considered in the design of prospective fit for purpose DBS biobanks, especially for those focused mostly on pediatric and OMIC platforms.
干血斑(DBS)由于采集所需时间和设备的减少以及处理、存储和运输的便利性,相较于其他血库方案具有许多优势。此外,由于样本量较小,当考虑储存儿科小样本时,DBS 是一种极具吸引力的方法。值得注意的是,疾病预防控制中心(CDC)的 DBS 预分析标准在全球基于质谱的先天性代谢缺陷筛查项目中被广泛应用。然而,这些指南可能不适用于未包含在这些方案中的分析物和方案。事实上,剩余样本的可用性以及对该方案以外的方案的持续关注,为我们提供了新的 DBS 生物库见解。在此,我们回顾了文献,以确定在设计针对特定目的的前瞻性 DBS 生物库时应考虑的指标,特别是对于那些主要针对儿科和 OMIC 平台的生物库。